Clovek Advisory
@saurabh.tyagi.6720
Noida
40+ Years of experience
SEBI Registration INA100014879
Trade Ideas
624
Opinions
1k
Followers
124k
Expertise
Value Investing
Dividend
Goal Based
Macro Views
Sector Tracker
Fundamental
Personal Finance
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Live Trade Views
Posts
shared an insight ⚡️ 9 mins ago
Azad Engineering Limited Q2 FY 27 Results Quick Look
AZAD Top-line growth (+23.6% YoY, +10.8% QoQ) signals continued demand/volume expansion in the quarter.
PAT decline (−5.2% YoY, −12% QoQ) despite revenue growth suggests margin pressure, higher costs or one‑offs impacting profitability.
Operating cash flow swung to a material negative: OCF −119 Cr (latest) vs +54 Cr prior — a major red flag on cash conversion and working-capital stress.
Valuation is elevated (P/E ~113) — market appears to price high future growth; weaker profits or cash conversion increases downside risk to the multiple.
Return metrics are moderate/low (ROE 9.09%, ROCE 11.9%) — current profitability levels may not justify the high PE unless growth and margins sustainably improve.
shared an insight ⚡️ 7 hours ago
Britannia Q2 FY27 16.6% Revenue Growth and 10.2% Profit Rise
BRITANNIA Top‑line acceleration (16.6% YoY in Q2) confirms continued volume and value recovery, supporting revenue trajectory.
Profit growth (+10.2% PAT) lags sales growth — operating profit (+8.5%) and H1 margins are below FY26, signalling margin compression/operating‑leverage headwinds.
Management cites input cost pressures (flour, palm oil, sugar, milk, fuel) but uses strategic covers — indicates margin risk remains tied to commodity moves.
Cash from operations remains positive but growth is modest: Rs 2,612 Cr latest vs Rs 2,491 Cr prior (+4.9%) — cash generation intact but not growing in step with sales.
High capital efficiency (ROE ~53.5%, ROCE ~56%) and large market cap (~Rs 120,684 Cr) mean results are material for market valuation — execution matters for re‑rating potential.
shared an insight ⚡️ 5th Nov
KIMS reports Q2 FY27 growth with 14.0% QoQ revenue increase
KIMS Capex intensity: cash flows from investing are strongly negative (–₹1,452 Cr vs –₹1,116 Cr prior), signalling heavy near-term investment and cash absorption for new hospitals/CWIP (CWIP ₹606 Cr).
Asset base: fixed assets ~₹5,710 Cr with CWIP shows an asset-heavy expansion; incremental beds materially increase capacity and future revenue potential once utilization ramps.
Profitability signal: ROCE has declined (latest ~10% from ~15%), indicating current returns are under pressure — new capacity must achieve strong utilisation to restore returns.
Valuation sensitivity: market cap ~₹31,104 Cr and high P/E (~149) imply the stock already prices future growth; execution shortfalls or slow ramp-up would hurt investor returns.
High-value services: addition of oncology, NICU and mother/child blocks increases potential ARPOB and margin mix if case mix and utilisation rise as expected.
FAQ's
What are the top stock recommendations by Clovek Advisory?
Clovek Advisory regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include Tata Consultancy Services Ltd. (Bullish), JK Paper Ltd. (Bullish), Blue Star Ltd. (Bullish), AZAD and BRITANNIA. Explore Clovek Advisory's complete list of posts and trade views on their StockGro profile.
How can I follow Clovek Advisory's latest investment insights?
You can follow Clovek Advisory's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is Clovek Advisory's investment strategy?
Clovek Advisory follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has Clovek Advisory been a SEBI-registered Research Analyst (RA)?
Clovek Advisory has been a SEBI-registered Research Analyst and have 40+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see Clovek Advisory's past performance and stock picks?
You can check Clovek Advisory's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact Clovek Advisory for stock market advice?
For stock market guidance from Clovek Advisory, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is Clovek Advisory's track record in predicting market movements?
Clovek Advisory has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for Clovek Advisory?
Clovek Advisory is a SEBI-registered Research Analyst with the SEBI Registration INA100014879. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro